CXCL14/BRAK Antibody AF866 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCXCL14/BRAK Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberAF866
NCBI Gene AliasesKS1, BMAC, KEC, MIP-2g, MIP2G, BRAK, NJAC, SCYB14
ApplicationsWestern Blot
ReactivityHuman
Conjugate/TagUnconjugated
Quantity100 ug (also 25 ug)
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
IsotypeIgG
TargetCXCL14/BRAK
HostGoat
NCBI Full Gene NameC-X-C motif chemokine ligand 14
ClonalityPolyclonal
ImmunogenE. coli-derived recombinant human CXCL14/BRAK (R&D Systems, Catalog # 866-CX), Ser23-Glu99, Accession # O95715
ConcentrationLYOPH
PurityAntigen Affinity-purified
Brand/TrademarkR&D Systems, a Bio-Techne Brand
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Unconjugated

Specificity: Detects human CXCL14/BRAK in direct ELISAs and Western blots. In direct ELISAs, less than 20% cross-reactivity with recombinant mouse CXCL14/BRAK is observed

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) C-X-C domain ligand 14-mediated stromal cell–macrophage interaction as a therapeutic target for hand dermal fibrosisCommunications BiologyNovember 18, 2023Atsushi Goto, Shingo Komura, Koki Kato, Rie Maki, Akihiro Hirakawa, Hiroyuki Tomita, Akihiro Hirata, Yasuhiro Yamada, Haruhiko Akiyamamedium with 20 µg/mL of a control IgG (AB-108-C; R&D Systems) or anti-CXCL14 neutralizing antibody (AF866; R&D Systems)50. A supernatant culture medium of murine dermal fibrotic cells derived from Tppp3-CreERT2/β-catenin

(2) p21 produces a bioactive secretome that places stressed cells under immunosurveillanceScience (New York, N.Y.)October 29, 2021Sturmlechner I, Zhang C, Sine CC, van Deursen EJ, Jeganathan KB, Hamada N, Grasic J, Friedman D, Stutchman JT, Can I, et al.p21-OE cells was added to a 24-well plate together with 20 μg/ml of goat anti-CXCL14 (R&D Systems, #AF866) or 20 μg/ml of goat anti-IgG (R&D Systems, #AB-108-C) (72). Transwell migration assays were performed

(3) Reduction in Human Epidermal Langerhans Cells with Age Is Associated with Decline in CXCL14-Mediated Recruitment of CD14⁺ MonocytesThe Journal of investigative dermatologyJuly 1, 2020Hasegawa T, Feng Z, Yan Z, Ngo KH, Hosoi J, Demehri S.counted. In CXCL14 antibody neutralization assay, 50 μg/mL CXCL14 neutralizing antibody (R&D systems, AF866 (Lu et al., 2015)) or Rat IgG antibody (R&D systems, 6-001-A) was added to the lower chamber of the

(4) Fascaplysin Exerts Anti-Cancer Effects through the Downregulation of Survivin and HIF-1α and Inhibition of VEGFR2 and TRKAInternational journal of molecular sciencesSeptember 29, 2017Oh TI, Lee YM, Nam TJ, Ko YS, Mah S, Kim J, Kim Y, Reddy RH, Kim YJ, Hong S, et al.

(5) The cytokine gene CXCL14 restricts human trophoblast cell invasion by suppressing gelatinase activityEndocrinologyDecember 1, 2009Kuang H, Chen Q, Zhang Y, Zhang L, Peng H, Ning L, Cao Y, Duan E.

(6) Activation of Wnt signalling in stroma from pancreatic cancer identified by gene expression profilingJournal of Cellular and Molecular MedicineDecember 2, 2008Christian Pilarsky et al.acids 285-299 of the human SFRP1 protein (1:50) [29] and a goat antibody against the CXCL14 protein (AF866; 1:50; R&D Systems, Minneapolis, MN, USA). As negative control specimens were incubated without the

(7) Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectivelyThe Journal of pathologyJune 1, 2005Tracey L, Pérez-Rosado A, Artiga MJ, Camacho FI, Rodríguez A, Martínez N, Ruiz-Ballesteros E, Mollejo M, Martinez B, Cuadros M, et al.

Be the First to Write a Review!

CXCL14/BRAK Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (7)

Reviews

CXCL14/BRAK Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map